

China Biologic Products, Inc.  
Form 8-K  
July 02, 2013

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest event Reported): June 28, 2013

**CHINA BIOLOGIC PRODUCTS, INC.**  
*(Exact name of registrant as specified in its charter)*

**Delaware**                                **001-34566**                                **75-2308816**  
*(State or other jurisdiction of (Commission File No.) (IRS Employer ID No.)  
incorporation or organization)*

**18th Floor, Jialong International Building  
19 Chaoyang Park Road  
Chaoyang District, Beijing 100125  
People's Republic of China  
(Address of Principal Executive Offices)**

**86 10 6598 3111**  
*Registrant's telephone number, including area code*

---

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Edgar Filing: China Biologic Products, Inc. - Form 8-K

- “ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
  
- “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
  
- “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

China Biologic Products, Inc. (the “Company”) held its 2013 Annual Meeting of Stockholders (the “Annual Meeting”) on Friday, June 28, 2013. Proxies for the Annual Meeting were solicited pursuant to the Company’s proxy statement filed on April 30, 2013 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934 (the “Proxy Statement”).

The Company’s stockholders considered three proposals, each of which is described in the Proxy Statement. A total of 22,381,959 shares were represented in person or by proxy, or 83.37% of the total shares outstanding. The final results of votes with respect to the proposals submitted for stockholder vote at the Annual Meeting are set forth below.

***Proposal 1 - Election of Directors***

Stockholders elected David (Xiaoying) Gao, Bing Li and Charles (Le) Zhang as Class I directors for a three-year term as follows:

<b>Director</b>	<b>For</b>	<b>Withhold</b>	<b>Abstain</b>
David (Xiaoying) Gao	16,867,429	151,906	5,362,624
Bing Li	16,867,429	151,906	5,362,624
Charles (Le) Zhang	16,867,429	151,906	5,362,624

***Proposal 2 - Ratification of the Selection of KPMG as the Company’s Independent Public Accounting Firm for the Fiscal Year ending December 31, 2013***

Stockholders ratified the selection of KPMG as the Company’s independent public accounting firm for the fiscal year ending December 31, 2013.

<b>For</b>	<b>Against</b>	<b>Abstain</b>
22,380,994	140	825

***Proposal 3 – Advisory Vote on Executive Compensation***

Edgar Filing: China Biologic Products, Inc. - Form 8-K

Stockholders approved the compensation of our named executive officers as disclosed in the Proxy Statement.

<b>For</b>	<b>Against</b>	<b>Abstain</b>
16,998,820	5,382,149	990

There were no broker non-votes for any of the proposals submitted for stockholder vote at the Annual Meeting.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 2, 2013 **CHINA BIOLOGIC PRODUCTS, INC.**

By: /s/David (Xiaoying) Gao

David (Xiaoying) Gao

Chief Executive Officer